2023 World Conference on Lung Cancer (Posters)-EP12.01. Validation of the ALK-Brain Prognostic Index (ALK-BPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases

EP12.01. Validation of the ALK-Brain Prognostic Index (ALK-BPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to validate the ALK-Brain Prognostic Index (ALK-BPI) model in patients with ALK-rearranged non-small cell lung cancer (NSCLC) and brain metastases who were treated with ALK inhibitors. The study included a retrospective analysis of 82 patients from Heidelberg University Hospital and 44 patients from Karolinska University Hospital. The median age of patients in the study was 58 years, with the majority having a performance status of 0-2 and 56.1% being female. The study found that gender and performance status were independently associated with brain metastasis-related overall survival (OS).<br /><br />The study also assessed the prognostic value of other clinical variables and scores, such as the DS-GPA and Lung-molGPA groups. Not all of these scores showed significant differences. However, the ALK-BPI-poor group, which is based on performance status, gender, and brain metastasis at diagnosis, was significantly associated with worse brain metastasis-related OS in both the validation cohort and the merged cohort.<br /><br />These findings provide additional validation for the ALK-BPI prognostic model in ALK lung cancer patients with brain metastases who are treated with ALK inhibitors. The study highlights the potential clinical utility of this model in predicting outcomes for these patients. Overall, this study contributes to the understanding of prognostic factors and outcomes in ALK-rearranged NSCLC with brain metastases and may help inform treatment decisions for these patients.

Asset Subtitle

Georgios Tsakonas

Meta Tag

Speaker Georgios Tsakonas

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

ALK-Brain Prognostic Index

ALK-rearranged non-small cell lung cancer

brain metastases

ALK inhibitors

performance status

gender

overall survival

prognostic model

clinical utility

treatment decisions